Bausch + Lomb Corporation reported its financial results for the third quarter of 2025, revealing a revenue of $1.281 billion, a 7% increase from $1.196 billion in the same period last year. The growth was primarily driven by increased product sales across its Pharmaceuticals and Vision Care segments, which saw volume increases of $76 million. However, the company also faced challenges, including a decrease in net realized pricing of $9 million and the impact of divestitures amounting to $4 million. For the nine months ended September 30, 2025, total revenues reached $3.696 billion, up from $3.511 billion in 2024, marking a 5% increase.
Despite the revenue growth, Bausch + Lomb reported a net loss attributable to the company of $28 million for the third quarter, compared to a net income of $4 million in the prior year. This decline was attributed to an increase in income tax provisions, which rose by $88 million, offsetting the benefits from improved operating results. Operating income for the quarter was $95 million, significantly higher than the $43 million reported in the same quarter of 2024. The company’s total expenses also increased, with selling, general, and administrative expenses rising to $528 million from $511 million, and research and development expenses increasing to $95 million from $84 million.
Strategically, Bausch + Lomb has been active in expanding its product portfolio through acquisitions. In 2025, the company acquired Whitecap Biosciences for approximately $28 million, which is expected to enhance its clinical-stage pipeline. Additionally, the company is in the process of acquiring manufacturing equipment and assets in Mexico, with an expected cash payment of $75 million. These acquisitions are part of Bausch + Lomb's strategy to bolster its offerings in the eye health market, which includes a comprehensive range of products across its Vision Care, Pharmaceuticals, and Surgical segments.
Operationally, Bausch + Lomb reported a slight increase in its employee headcount, reflecting its ongoing investments in product development and market expansion. The company continues to monitor market conditions, including the impact of the ongoing Russia-Ukraine conflict and geopolitical tensions in the Middle East, which have not yet materially affected its operations. Looking ahead, Bausch + Lomb anticipates continued revenue growth driven by its diverse product portfolio and strategic acquisitions, although it remains cautious about potential challenges related to market conditions and pricing pressures.
In summary, Bausch + Lomb's third-quarter results indicate a positive revenue trajectory, bolstered by strategic acquisitions and product sales growth, despite facing net losses and increased expenses. The company is focused on enhancing its market position while navigating external challenges and preparing for future growth opportunities.
About Bausch & Lomb Corp
Bausch + Lomb Corporation is a global eye health company offering a comprehensive portfolio of approximately 400 products across Vision Care, Pharmaceuticals, and Surgical segments. Its products include contact lenses, lens care solutions, ophthalmic pharmaceuticals, intraocular lenses, and surgical devices. Serving patients, consumers, and eye care professionals worldwide, Bausch + Lomb leverages innovation, strong brand equity, and integrated R&D to address diverse eye health needs through a fully integrated business model.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.